Eyebright Medical Technology (Beijing) Co., Ltd. (SHA:688050)
China · Delayed Price · Currency is CNY 59.50
-0.45 (-0.75%)
Feb 13, 2026, 3:00 PM CST
SHA:688050 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,473 | 1,404 | 947.42 | 575.86 | 431.2 | 272.62 |
Other Revenue | 6.4 | 6.4 | 3.75 | 3.64 | 1.87 | 0.43 |
| 1,479 | 1,410 | 951.18 | 579.5 | 433.07 | 273.05 | |
Revenue Growth (YoY) | 8.89% | 48.24% | 64.14% | 33.81% | 58.61% | 39.88% |
Cost of Revenue | 527.88 | 479.83 | 230.04 | 88.35 | 68.08 | 43.97 |
Gross Profit | 951.29 | 930.19 | 721.14 | 491.15 | 364.99 | 229.08 |
Selling, General & Admin | 434.64 | 370.67 | 296.94 | 178.57 | 142.27 | 96.03 |
Research & Development | 98.99 | 106.42 | 91.95 | 63.9 | 51.91 | 29.99 |
Other Operating Expenses | 7.66 | 4.75 | 14.98 | 8.69 | 7.17 | 3.97 |
Operating Expenses | 552.32 | 492.69 | 412.99 | 259.52 | 207.1 | 132.01 |
Operating Income | 398.97 | 437.5 | 308.16 | 231.62 | 157.89 | 97.06 |
Interest Expense | -22.74 | -20.73 | -9.81 | -2.02 | -0.74 | - |
Interest & Investment Income | 6.41 | 4.17 | 19.98 | 21.97 | 25.56 | 10.55 |
Currency Exchange Gain (Loss) | -0.46 | -0.46 | 0.62 | -0.23 | -0.92 | 0.42 |
Other Non Operating Income (Expenses) | 2.01 | -0.29 | 0.03 | -0.52 | -0.15 | -0.06 |
EBT Excluding Unusual Items | 384.19 | 420.19 | 318.97 | 250.81 | 181.65 | 107.96 |
Gain (Loss) on Sale of Investments | -0.62 | -0.69 | -1.84 | 1.49 | 0.2 | 0.28 |
Gain (Loss) on Sale of Assets | -0.23 | -0.08 | 0.11 | 0.01 | 0.02 | -0.15 |
Asset Writedown | -5.49 | -1.98 | - | - | - | - |
Other Unusual Items | 13.82 | 13.65 | 10.43 | 11.77 | 5.9 | 2.95 |
Pretax Income | 391.68 | 431.1 | 327.67 | 264.08 | 187.77 | 111.04 |
Income Tax Expense | 30.02 | 44.02 | 41.62 | 36.85 | 20.01 | 14.92 |
Earnings From Continuing Operations | 361.66 | 387.08 | 286.05 | 227.23 | 167.75 | 96.12 |
Minority Interest in Earnings | -0.69 | 1.32 | 17.93 | 5.46 | 3.59 | 0.44 |
Net Income | 360.97 | 388.4 | 303.98 | 232.69 | 171.34 | 96.56 |
Net Income to Common | 360.97 | 388.4 | 303.98 | 232.69 | 171.34 | 96.56 |
Net Income Growth | -2.33% | 27.77% | 30.63% | 35.80% | 77.45% | 44.80% |
Shares Outstanding (Basic) | 192 | 189 | 189 | 190 | 189 | 161 |
Shares Outstanding (Diluted) | 192 | 189 | 190 | 190 | 189 | 161 |
Shares Change (YoY) | 1.12% | -0.27% | 0.25% | 0.17% | 17.57% | 13.96% |
EPS (Basic) | 1.88 | 2.05 | 1.61 | 1.23 | 0.91 | 0.60 |
EPS (Diluted) | 1.88 | 2.05 | 1.60 | 1.23 | 0.91 | 0.60 |
EPS Growth | -3.42% | 28.13% | 30.31% | 35.58% | 50.93% | 27.07% |
Free Cash Flow | 215.48 | 18.27 | -157.72 | -20.9 | -91.92 | 4.62 |
Free Cash Flow Per Share | 1.12 | 0.10 | -0.83 | -0.11 | -0.49 | 0.03 |
Dividend Per Share | 0.350 | 0.350 | 0.272 | 0.283 | 0.206 | 0.156 |
Dividend Growth | 28.58% | 28.58% | -3.92% | 37.79% | 32.13% | - |
Gross Margin | 64.31% | 65.97% | 75.82% | 84.75% | 84.28% | 83.90% |
Operating Margin | 26.97% | 31.03% | 32.40% | 39.97% | 36.46% | 35.55% |
Profit Margin | 24.40% | 27.55% | 31.96% | 40.15% | 39.56% | 35.36% |
Free Cash Flow Margin | 14.57% | 1.30% | -16.58% | -3.61% | -21.22% | 1.69% |
EBITDA | 568.94 | 565.64 | 380.52 | 271.42 | 188.07 | 123.73 |
EBITDA Margin | 38.46% | 40.12% | 40.01% | 46.84% | 43.43% | 45.31% |
D&A For EBITDA | 169.97 | 128.14 | 72.36 | 39.79 | 30.18 | 26.67 |
EBIT | 398.97 | 437.5 | 308.16 | 231.62 | 157.89 | 97.06 |
EBIT Margin | 26.97% | 31.03% | 32.40% | 39.97% | 36.46% | 35.55% |
Effective Tax Rate | 7.66% | 10.21% | 12.70% | 13.95% | 10.66% | 13.44% |
Revenue as Reported | 1,479 | 1,410 | 951.18 | 579.5 | 433.07 | 273.05 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.